Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
Wakunaga
The Kyolic garlic supplement maker is launching a new line of dietary supplements including Echinacea-Go!, Ginseng-Go!, St. John's Wort-Go! and Una De Gato-Go! The one-per-day capsules will be sold in most outlets that carry the Kyolic brand. Suggested retail prices range from $9.99 for a 60-count bottle of the St. John's wort product to $24.99 for the 60-count yeast, sodium and dairy-free ginseng extract product. No ads are planned for the new line. Mission Viejo, Calif.-based Wakunaga of America is one of the first NNFA member companies to be certified under the association's new GMP program (1see story, p. 16)
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.
• By
The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.
• By
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.